← Leaderboards
Luis J. Montaner
Wistar Institute
$69,201,825
Attributed
$112,577,453
Total exposure
31
Grants
23
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $11M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$112,577,453 · 31
By mechanism
UM1$57,168,490 · 3
R01$37,106,321 · 13
U01$12,928,645 · 3
P30$2,421,873 · 3
S10$1,640,290 · 4
R21$1,161,294 · 3
Top collaborators
- James L Riley11 shared
- Edmundo Nelson Kraiselburd7 shared
- David S Metzger6 shared
- Robert F Siliciano6 shared
- David W. Speicher5 shared
- Valerian E Kagan4 shared
- Drew Weissman1 shared
Most similar at Wistar Institute
Same institution · by research overlap
- Valerian E Kagan$31,774,048
- Wolfgang Weninger$728,237
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsImmuneHiv-1ViralBaseResponseHiv InfectionsMediatingResearch PersonnelClinical TrialsBloodInstitutesUniversitiesTissuesDendritic CellsNatural Killer CellsProgramsClinical ResearchInfectionFundingPhenotypeAntiretroviral TherapyImmunotherapyFlow Cytometry
Grant awards (111)
BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy$5,626,081
UM1 · FY2025 · AI · contact PI
Individualized HIV Curative Combination Strategy against Persistent HIV on ART$3,568,644
UM1 · FY2025 · AI · contact PI
Biomedical Research Support Shared Resource$158,300
P30 · FY2025 · CA · contact PI
Flow Cytometry Shared Resource$117,114
P30 · FY2025 · CA · contact PI
BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy$5,736,593
UM1 · FY2024 · AI · contact PI
BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy$5,780,735
UM1 · FY2023 · AI · contact PI
Effects of mu-opiate receptor engagement on microbial translocation and residual immune activation in HIV-infected, ART suppressed opioid use disorder patents initiating medication-assisted treatment$1,621,237
R01 · FY2023 · DA · contact PI
Effects of Mu-opiate receptor engagement on the persistence of HIV-associated activation and viral reservoirs in individuals receiving medication assisted treatment for opioid use disorder$766,227
R01 · FY2023 · DA · contact PI
Biomedical Research Support Shared Resource$171,497
P30 · FY2023 · CA · contact PI
Flow Cytometry Shared Resource$108,591
P30 · FY2023 · CA · contact PI
BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy$5,839,685
UM1 · FY2022 · AI · contact PI
Effects of mu-opiate receptor engagement on microbial translocation and residual immune activation in HIV-infected, ART suppressed opioid use disorder patents initiating medication-assisted treatment$1,652,477
R01 · FY2022 · DA · contact PI
Effects of Mu-opiate receptor engagement on the persistence of HIV-associated activation and viral reservoirs in individuals receiving medication assisted treatment for opioid use disorder$925,573
R01 · FY2022 · DA · contact PI
Lipids and Myeloid Cell Function in Cancer$394,195
R01 · FY2022 · CA · contact PI
Biomedical Research Support Shared Resource$171,497
P30 · FY2022 · CA · contact PI
Purchase of MVE Fusion Self-Sustaining Cryogenic Freezers$110,540
R24 · FY2022 · OD · contact PI
Flow Cytometry Shared Resource$108,591
P30 · FY2022 · CA · contact PI
BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy$6,099,975
UM1 · FY2021 · AI · contact PI
Effects of mu-opiate receptor engagement on microbial translocation and residual immune activation in HIV-infected, ART suppressed opioid use disorder patents initiating medication-assisted treatment$1,678,538
R01 · FY2021 · DA · contact PI
First-in-human study of two anti-SARS CoV-2 antibodies in health volunteers$1,571,599
UM1 · FY2021 · AI · contact PI
Effects of Mu-opiate receptor engagement on the persistence of HIV-associated activation and viral reservoirs in individuals receiving medication assisted treatment for opioid use disorder$764,910
R01 · FY2021 · DA · contact PI
Lipids and Myeloid Cell Function in Cancer$402,239
R01 · FY2021 · CA · contact PI
Biomedical Research Support Shared Resource$171,497
P30 · FY2021 · CA · contact PI
Effects of Mu-opiate receptor engagement on the persistence of HIV-associated activation and viral reservoirs in individuals receiving medication assisted treatment for opioid use disorder$156,933
R01 · FY2021 · DA · contact PI
Flow Cytometry Shared Resource$108,591
P30 · FY2021 · CA · contact PI
BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy$4,589,035
UM1 · FY2020 · AI · contact PI
Effects of mu-opiate receptor engagement on microbial translocation and residual immune activation in HIV-infected, ART suppressed opioid use disorder patents initiating medication-assisted treatment$1,657,600
R01 · FY2020 · DA · contact PI
Effects of Mu-opiate receptor engagement on the persistence of HIV-associated activation and viral reservoirs in individuals receiving medication assisted treatment for opioid use disorder$761,421
R01 · FY2020 · DA · contact PI
Lipids and Myeloid Cell Function in Cancer$402,239
R01 · FY2020 · CA · contact PI
Biomedical Research Support Shared Resource$159,250
P30 · FY2020 · CA · contact PI
Flow Cytometry Shared Resource$100,838
P30 · FY2020 · CA · contact PI
BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy$4,589,036
UM1 · FY2019 · AI · contact PI
Effects of mu-opiate receptor engagement on microbial translocation and residual immune activation in HIV-infected, ART suppressed opioid use disorder patents initiating medication-assisted treatment$1,248,932
R01 · FY2019 · DA · contact PI
Effects of Mu-opiate receptor engagement on the persistence of HIV-associated activation and viral reservoirs in individuals receiving medication assisted treatment for opioid use disorder$827,942
R01 · FY2019 · DA · contact PI
Effects of mu-opiate receptor engagement on microbial translocation and residual immune activation in HIV-infected, ART suppressed opioid use disorder patents initiating medication-assisted treatment$515,107
R01 · FY2019 · DA · contact PI
Lipids and Myeloid Cell Function in Cancer$390,171
R01 · FY2019 · CA · contact PI
Biomedical Research Support Shared Resource$171,497
P30 · FY2019 · CA · contact PI
Flow Cytometry Shared Resource$108,592
P30 · FY2019 · CA · contact PI
BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy$4,589,036
UM1 · FY2018 · AI · contact PI
BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy$4,589,035
UM1 · FY2017 · AI · contact PI
Towards Eradication: Reducing Proviral HIV DNA with Interferon-α Immunotherapy$1,713,149
U01 · FY2017 · AI · contact PI
BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy$4,589,036
UM1 · FY2016 · AI · contact PI
Towards Eradication: Reducing Proviral HIV DNA with Interferon-α Immunotherapy$1,837,344
U01 · FY2016 · AI · contact PI
Towards Eradication: Reducing Proviral HIV DNA with Interferon-α Immunotherapy$1,939,835
U01 · FY2015 · AI · contact PI
Early Innate/IgA Anti-HIV/SIV Response in Exposed Uninfected$735,463
R01 · FY2015 · AI · contact PI
Towards Eradication: Reducing Proviral HIV DNA with Interferon-a Immunotherapy$1,708,367
U01 · FY2014 · AI · contact PI
Early Innate/IgA Anti-HIV/SIV Response in Exposed Uninfected$763,552
R01 · FY2014 · AI · contact PI
NK Cell Activation and Function in HIV-1 Exposed Uninfected IV Drug Users$701,027
R01 · FY2014 · DA · contact PI
Purchase a Beckman Coulter MoFlo Astrios Flow Cytometer$594,850
S10 · FY2014 · OD · contact PI
Early Innate/IgA Anti-HIV/SIV Response in Exposed Uninfected$731,492
R01 · FY2013 · AI · contact PI
NK Cell Activation and Function in HIV-1 Exposed Uninfected IV Drug Users$678,291
R01 · FY2013 · DA · contact PI
Flow Cytometry$138,869
P30 · FY2013 · CA · contact PI
Early Innate/IgA Anti-HIV/SIV Response in Exposed Uninfected$728,314
R01 · FY2012 · AI · contact PI
NK Cell Activation and Function in HIV-1 Exposed Uninfected IV Drug Users$678,940
R01 · FY2012 · DA · contact PI
Flow Cytometry$151,413
P30 · FY2012 · CA · contact PI
Early Innate/IgA Anti-HIV/SIV Response in Exposed Uninfected$829,776
R01 · FY2011 · AI · contact PI
NK/DC Cross-Talk and Antiviral Response$772,006
R01 · FY2011 · AI · contact PI
NK Cell Activation and Function in HIV-1 Exposed Uninfected IV Drug Users$665,484
R01 · FY2011 · DA · contact PI
Flow Cytometry$152,048
P30 · FY2011 · CA · contact PI
NK/DC Cross-Talk and Antiviral Response$792,714
R01 · FY2010 · AI · contact PI
Cellular innate activation as a tactic to prevent HIV-1 transmission$742,074
R01 · FY2010 · AI · contact PI
NK Cell Activation and Function in HIV-1 Exposed Uninfected IV Drug Users$665,385
R01 · FY2010 · DA · contact PI
Pediatric Immune Correlates of Early Anti-HIV Therapy$515,049
R01 · FY2010 · AI · contact PI
HIV Therapy & Interruption RCT in Resource Poor Clinic$388,769
U01 · FY2010 · AI · contact PI
Flowcore Upgrade: Amnis ImageStream Flow Cytometer$363,500
S10 · FY2010 · RR · contact PI
Innate Effector Function and HIV-1 Control$205,029
R21 · FY2010 · AI · contact PI
Flow Cytometry$165,705
P30 · FY2010 · CA · contact PI
Cellular innate activation as a tactic to prevent HIV-1 transmission$816,329
R01 · FY2009 · AI · contact PI
NK/DC Cross-Talk and Antiviral Response$810,038
R01 · FY2009 · AI · contact PI
HIV Therapy & Interruption RCT in Resource Poor Clinic$656,640
U01 · FY2009 · AI · contact PI
Pediatric Immune Correlates of Early Anti-HIV Therapy$588,935
R01 · FY2009 · AI · contact PI
Antiviral activity of Peg-IFN alpha in chronic HIV-1$502,174
U01 · FY2009 · AI · contact PI
Flowcore Upgrade: BD FACSAria II High-Speed Cell Sorter$466,004
S10 · FY2009 · RR · contact PI
Innate Effector Function and HIV-1 Control$262,399
R21 · FY2009 · AI · contact PI
Flow Cytometry$157,983
P30 · FY2009 · CA · contact PI
Tri-Society Meeting of International Cytokine Society (ICS), International Societ$40,000
R13 · FY2009 · CA · contact PI
NK/DC Cross-Talk and Antiviral Response$632,784
R01 · FY2008 · AI · contact PI
Antiviral activity of Peg-IFN alpha in chronic HIV-1$582,803
U01 · FY2008 · AI · contact PI
Pediatric Immune Correlates of Early Anti-HIV Therapy$576,212
R01 · FY2008 · AI · contact PI
HIV Therapy & Interruption RCT in Resource Poor Clinic$619,730
U01 · FY2007 · AI · contact PI
Pediatric Immune Correlates of Early Anti-HIV Therapy$590,873
R01 · FY2007 · AI · contact PI
Antiviral activity of Peg-IFN alpha in chronic HIV-1$581,270
U01 · FY2007 · AI · contact PI
HIV Therapy & Interruption RCT in Resource Poor Clinic$647,069
U01 · FY2006 · AI · contact PI
Pediatric Immune Correlates of Early Anti-HIV Therapy$581,670
R01 · FY2006 · AI · contact PI
Antiviral activity of Peg-IFN alpha in chronic HIV-1$576,065
U01 · FY2006 · AI · contact PI
HIV Therapy &Interruption RCT in Resource Poor Clinic$657,359
U01 · FY2005 · AI
Antiviral activity of Peg-IFN alpha in chronic HIV-1$518,071
U01 · FY2005 · AI
Pediatric Immune Correlates of Early Anti-HIV Therapy$470,339
R01 · FY2005 · AI
APCs and Innate Immunity in HIV Disease$397,681
R01 · FY2005 · AI
HIV Therapy &Interruption RCT in Resource Poor Clinic$653,051
R01 · FY2004 · AI
APCs and Innate Immunity in HIV Disease$392,001
R01 · FY2004 · AI
ANTI-HIV-1 EFFECTS OF IL-13 ON MACROPHAGES AND T CELLS$309,896
R01 · FY2004 · AI
Immune Determinants to Bacterial and Viral Co-Infection$252,412
R21 · FY2004 · AI
IMMUNE AND VIRAL OUTCOMES OF HIV-1 THERAPY INTERRUPTION$635,690
R01 · FY2003 · AI
APCs and Innate Immunity in HIV Disease$386,540
R01 · FY2003 · AI
IMMUNOBIOLOGY OF INTERLUKIN-12$360,789
R01 · FY2003 · AI
HIV Therapy &Interruption RCT in Resource Poor Clinic$329,964
R01 · FY2003 · AI
ANTI-HIV-1 EFFECTS OF IL-13 ON MACROPHAGES AND T CELLS$305,668
R01 · FY2003 · AI
Immune Determinants to Bacterial and Viral Co-Infection$248,949
R21 · FY2003 · AI
IMMUNE AND VIRAL OUTCOMES OF HIV-1 THERAPY INTERRUPTION$569,348
R01 · FY2002 · AI
APCs and Innate Immunity in HIV Disease$381,287
R01 · FY2002 · AI
IMMUNOBIOLOGY OF INTERLUKIN-12$352,022
R01 · FY2002 · AI
ANTI-HIV-1 EFFECTS OF IL-13 ON MACROPHAGES AND T CELLS$301,605
R01 · FY2002 · AI
IMMUNE AND VIRAL OUTCOMES OF HIV-1 THERAPY INTERRUPTION$634,372
R01 · FY2001 · AI
IMMUNOBIOLOGY OF INTERLUKIN-12$343,509
R01 · FY2001 · AI
ANTI-HIV-1 EFFECTS OF IL-13 ON MACROPHAGES AND T CELLS$297,697
R01 · FY2001 · AI
FLOW CORE UPGRADE--CYTOMATION MOFLO CYTOFLUORIMETER$215,936
S10 · FY2001 · RR
IMMUNE AND VIRAL OUTCOMES OF HIV-1 THERAPY INTERRUPTION$568,529
R01 · FY2000 · AI
IMMUNOBIOLOGY OF INTERLUKIN-12$335,245
R01 · FY2000 · AI
ANTI HIV 1 EFFECTS OF IL 13 ON MACROPHAGES AND T CELLS$318,939
R01 · FY2000 · AI
IL-13 EFFECTS ON ANTIGEN PRESENTATION IN HIV1 INFECTION$192,505
R21 · FY2000 · AI